Bioactivity-guided isolation and identification of anti-adipogenic compounds from
            <i>Sanguisorba officinalis</i>

Im, Sun Hyuk; Wang, Zhiqiang; Lim, Soon Sung; Lee, Ok‐Hwan; Kang, Il‐Jun

doi:10.1080/13880209.2017.1357736

Cited by 20 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A loss in the mitochondria membrane potential and up-regulation of adiponectin was observed as well (Hsu and Yen, 2007). Some polyphenols such as isorhamnetin-3-O-D-glucuronide and ellagic acid isolated from Sanguisorba officinalis Linne also possess antiadipogenic properties (Im et al, 2017). Flavonoid glycosides (astragalin, isoquercetin, rhamnocitrin 3-O-glucoside, and nicotiflorin), triterpenes (methyl hederagenin) and triterpene glycosides (hederin, echinocystic acid 3-O-arabinoside and cauloside B) had a regulatory role in adipocytes differentiation.…”

Section: In Vitro Studiesmentioning

confidence: 96%

Causes and solutions to “globesity”: The new fa(s)t alarming global epidemic

Vasileva

Marchev

Georgiev

2018

Food and Chemical Toxicology

View full text Add to dashboard Cite

Diverse groups of factors are leading to increased weight gain and obesity, such as certain genetic phenotypes, neuroendocrine disturbances, the administration of some drugs, behavioral, social and environmental factors. The progressively escalating rates of overweight and obesity worldwide have led to an introduction of a new term "globesity". Excessive accumulation of body fat and especially of visceral adipose tissue is the main predisposing factor for the development of metabolic syndrome and other obesity related co-morbidities. At the present moment only few pharmacotherapeuticals are used for long-term treatment of obesity acting on narrow target spectra, e.g. pancreatic and gastric lipase inhibition, acting as adrenomimetics or activating the satiety centers in hypothalamus. Plant-based medications that accelerate weight loss, proved to be safe, effective and widely available, would be a preferable alternative for anti-obesity treatments. As plant extracts are multi-component systems they could also act by more than one mechanism, including decreased lipid absorption, decreased energy intake, increased energy expenditure, decreased pre-adipocyte differentiation and proliferation, decreased lipogenesis and increased lipolysis. The current review gives a summary of the risk factors for obesity development and its characteristics consequences. Current treatment options, combining lifestyle changes and conventional treatment with commercial anti-obesity drugs have been described as well. Special emphasis on in vitro, in vivo and human studies, of potential medicinal plant extracts and phytochemicals, such as polyphenols, terpenoids, alkaloids, saponins, able to modulate the molecular pathways and gene/protein expressions related to obesity, have been highlighted.

show abstract

Section: In Vitro Studiesmentioning

confidence: 96%

Causes and solutions to “globesity”: The new fa(s)t alarming global epidemic

Vasileva

Marchev

Georgiev

2018

Food and Chemical Toxicology

View full text Add to dashboard Cite

show abstract

“…The Plant List ( The Plant List, 2021 ), International Plant Name Index ( International Plant Name Index, 2021 ) and Kew Botanical Garden ( Kew Botanical Garden, 2021a ; Kew Botanical Garden, 2021b ) were used for obtaining the scientific names and information on the subspecies and cultivars. Studies have demonstrated that the crude extracts from plants belonging to genus Sanguisorba or the purified monomers isolated from the plants of this genus exhibit various pharmacological activities, including anti-inflammatory ( Su et al, 2018a ; Guo et al, 2019 ; Yasueda et al, 2020 ), anti-cancer ( Liu et al, 2016 ; Nam et al, 2017 ; Tan et al, 2019 ; Bai et al, 2020a ; Liao et al, 2020 ), anti-lipid peroxidation ( Zhang et al, 2012a ; Romojaro et al, 2013a ; Kim et al, 2018a ; Lenzi et al, 2019 ), anti-bacteria ( Su et al, 2019 ; Zhu et al, 2020a ), anti-diabetes ( Kuang et al, 2011 ; Son et al, 2015 ), hepatoprotective ( Stojiljković et al, 2019 ; Meng et al, 2020 ), and anti-obesity ( Jung et al, 2016 ; Im et al, 2017 ; Ji et al, 2018 ) properties, both in vitro and in vivo ( Figure1 ).…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive Review of Genus Sanguisorba: Traditional Uses, Chemical Constituents and Medical Applications

Zhou

Chen

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Genus Sanguisorba (family: Rosaceae) comprises nearly 148 species, distributed widely across the temperate and subtropical regions of the Northern Hemisphere. Sanguisorba officinalis L. (S. officinalis) has been used as a hemostatic and scald treating medicine in China for a long time. Numerous studies have demonstrated that plant extracts or monomers from S. officinalis exhibit several pharmacological effects, such as anti-cancer, anti-virus, anti-inflammation, anti-bacteria, neuroprotective and hepatoprotective effects. The other species of genus Sanguisorba are also being studied by researchers worldwide. Sanguisorba minor Scop. (S. minor), as an edible wild plant, is a common ingredient of the Mediterranean diet, and its young shoots and leaves are often mixed with traditional vegetables and consumed as salad. Reports on genus Sanguisorba available in the current literature were collected from Google Scholar, Web of Science, Springer, and PubMed. The Plant List (http://www.theplantlist.org./tpl1.1/search?q=Sanguisorba), International Plant Name Index (https://www.ipni.org/?q=Sanguisorba) and Kew Botanical Garden (http://powo.science.kew.org/) were used for obtaining the scientific names and information on the subspecies and cultivars. In recent years, several in vivo and in vitro experiments have been conducted to reveal the active components and effective monomers of S. officinalis and S. minor. To date, more than 270 compounds have been isolated and identified so far from the species belonging to genus Sanguisorba. Numerous reports on the chemical constituents, pharmacologic effects, and toxicity of genus Sanguisorba are available in the literature. This review provides a comprehensive understanding of the current traditional applications of plants, which are supported by a large number of scientific experiments. Owing to these promising properties, this species is used in the treatment of various diseases, including influenza virus infection, inflammation, Alzheimer’s disease, type 2 diabetes and leukopenia caused by bone marrow suppression. Moreover, the rich contents and biological effects of S. officinalis and S. minor facilitate these applications in dietary supplements and cosmetics. Therefore, the purpose of this review is to summarize the recent advances in the traditional uses, chemical constituents, pharmacological effects and clinical applications of genus Sanguisorba. The present comprehensive review may provide new insights for the future research on genus Sanguisorba.

show abstract

“…The Sanguisorba officinalis L ( Figure 1 ), a traditional Chinese medicine which has been used in China for nearly 1000 years, has wide pharmacological activities including hemostasis, antidiarrheal, antineoplastic and increasing leucocytes. 10 The Sanguisorba officinalis is only needed 5 mg to treat leukopenia. Our previous study has confirmed that the Ziyuglycoside I (ZgI) ( Figure 1 ) is the crucial component of the Sanguisorba officinalis , which has prominent activity to increase the leucocytes.…”

Section: Introductionmentioning

confidence: 99%

TPGS-Modified Long-Circulating Liposomes Loading Ziyuglycoside I for Enhanced Therapy of Myelosuppression

Song¹,

Wang²,

Liu³

et al. 2021

IJN

View full text Add to dashboard Cite

Background Ziyuglycoside I (ZgI), an active ingredient isolated from traditional Chinese medicine Sanguisorba officinalis L, has been demonstrated to increase the leucocytes and protect hematopoietic stem cells. However, the poor solubility and a short half-life of ZgI limit its bioavailability and efficacy. The D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) has been widely used to increase the solubility, improve the encapsulation rate, and extend the half-life of drugs. Methods Here, we formulated the TPGS-modified long-circulating liposomes loading ZgI with a sustained drug release and enhanced therapy for myelosuppression. ZgI-TPGS-liposomes were manufactured using a thin-film hydration technique, followed by characterizations of physicochemical properties, including the particle size, zeta potential, TEM, SEM, FTIR, XRD, stability, drug loading (DL), encapsulation efficiency (EE). The in vitro and in vivo delivery efficiency were further evaluated by cellular uptake, in vitro drug release and in vivo pharmacokinetics. Finally, therapeutic effect on myelosuppression was investigated. Results The ZgI-TPGS-liposomes had an particle size of 97.89 ± 1.42 nm and ZP of −28.65 ± 0.16 mV. It exhibited DL of 9.06 ± 0.76% and EE of 92.34 ± 3.83%, along with excellent storage stability, cellular uptake and sustained drug release to free ZgI and liposomes without TPGS. Additionally, the TPGS modified liposomes significantly enhanced the therapeutic effect of ZgI on CTX induced myelosuppression, which can be confirmed in the apoptosis inhibition and cell viability promotion of CTX injured HSPC-1 cells. Also, the mice in vivo pharmacodynamics demonstrated that TPGS liposomes promoted ZgI increasing the numbers of leucocytes and neutrophils in myelosuppression mice induced by CTX. Conclusion Our research suggest that TPGS-modified long-circulating liposomes loading ziyuglycoside I has potential application in myelosuppression therapy.

show abstract

Bioactivity-guided isolation and identification of anti-adipogenic compounds from Sanguisorba officinalis

Cited by 20 publications

References 18 publications

Causes and solutions to “globesity”: The new fa(s)t alarming global epidemic

Causes and solutions to “globesity”: The new fa(s)t alarming global epidemic

A Comprehensive Review of Genus Sanguisorba: Traditional Uses, Chemical Constituents and Medical Applications

TPGS-Modified Long-Circulating Liposomes Loading Ziyuglycoside I for Enhanced Therapy of Myelosuppression

Contact Info

Product

Resources

About